Cover Image

Allostatic load increases the incidence and risk of adverse prognosis in inflammatory bowel disease

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Authors:	Jianhui Zhao, Erxu Xue, Siyun Zhou, Meng Zhang, Fangyuan Jiang, Wei Wu, Zhanju Liu, Xue Li
Format:	Artículo Open Access
Published:	Wiley 2024
Subjects:	Alimentary Pharmacology & Therapeutics
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Editorial: Allostatic Load and Inflammatory Bowel Disease. Authors' Reply
by: Jianhui Zhao, et al.
Published: (2024)

Letter: Allostatic Load and Adverse Prognosis in Inflammatory Bowel Disease—Need More Evidence. Authors' Reply
by: Jianhui Zhao, et al.
Published: (2024)

Letter: Allostatic load—A potential key in the development of inflammatory bowel disease
by: Maryam Kharal, et al.
Published: (2024)

The contribution of dietary advanced glycation end‐products and genetic risk in the development of inflammatory bowel disease: a prospective cohort study
by: Fangyuan Jiang, et al.
Published: (2024)

Impact of inflammatory bowel disease on the risk of acute coronary syndrome: A Swedish Nationwide Cohort Study
by: Carl Eriksson, et al.
Published: (2024)

Review article: Prevention of inflammatory bowel disease—The path forward
by: Sérgio Bronze, et al.
Published: (2024)

Editorial: GLP‐1 receptor agonists in inflammatory bowel disease—Is it time?
by: Konstantinos Arvanitakis, et al.
Published: (2024)

Review article: Novel therapies in inflammatory bowel disease – An update for clinicians
by: Nurulamin M. Noor, et al.
Published: (2024)

Meta‐analysis: Persistence of advanced therapies in the treatment of inflammatory bowel disease
by: Tsz Hong Yiu, et al.
Published: (2024)

Review article: Evidence‐based dietary management of inflammatory bowel disease
by: Peter R. Gibson, et al.
Published: (2024)

Editorial: Treatments for inflammatory bowel disease across the age‐spectrum—Are they the same?
by: Agnes Hiu Yan Ho, et al.
Published: (2024)

Letter: Thioguanine, an under‐utilised option in inflammatory bowel disease? Authors' reply
by: Abhinav Vasudevan, et al.
Published: (2024)

Editorial: Towards optimal thiopurine therapy for inflammatory bowel disease—authors' reply
by: Abhinav Vasudevan, et al.
Published: (2024)

Paediatric‐onset immune‐mediated inflammatory disease is associated with an increased mortality risk—A nationwide study
by: Mikkel Malham, et al.
Published: (2024)

Oral vancomycin is associated with improved inflammatory bowel disease clinical outcomes in primary sclerosing cholangitis‐associated inflammatory bowel disease (PSC‐IBD): A matched analysis from the Paediatric PSC Consortium
by: Amanda Ricciuto, et al.
Published: (2024)

Review article: Optimisation of biologic (monoclonal antibody) therapeutic response in inflammatory bowel disease
by: Thanaboon Chaemsupaphan, et al.
Published: (2024)

Systematic review: Methotrexate—A poorly understood and underused medication in inflammatory bowel disease
by: Léa Sequier, et al.
Published: (2024)

Review article: A practical approach to persistent gastrointestinal symptoms in inflammatory bowel disease in remission
by: Arta Aliu, et al.
Published: (2024)

Letter: Light in the lumen—The expanding role of intestinal ultrasound for functional symptoms in inflammatory bowel disease
by: R. M. Mathias, et al.
Published: (2024)

Review article: The role of the gut–brain axis in inflammatory bowel disease and its therapeutic implications
by: Christy Riggott, et al.
Published: (2024)

Letter: Diet‐microbiome interactions in inflammatory bowel disease—Navigating towards individualised dietary strategies
by: Iris Barth, et al.
Published: (2024)

Letter: Microbial manipulation for primary sclerosing cholangitis‐associated inflammatory bowel disease—hope on the horizon
by: D. Bogatic, et al.
Published: (2024)

Editorial: Allostatic Load and Inflammatory Bowel Disease
by: Jeli Mendoza, et al.
Published: (2024)

Editorial: Is it time to include oral vancomycin in therapeutic guidelines for primary sclerosing cholangitis‐associated inflammatory bowel disease?
by: Ayesha Shah, et al.
Published: (2024)

Use of glucagon‐like peptide‐1 receptor agonists for type 2 diabetes mellitus and outcomes of inflammatory bowel disease
by: Aakash Desai, et al.
Published: (2024)

Inflammatory bowel disease in 2024 and beyond
by: Richard B. Gearry, et al.
Published: (2024)

Application of clinical decision support tools for predicting outcomes with vedolizumab therapy in patients with inflammatory bowel disease: A KASID multicentre study
by: Kyuwon Kim, et al.
Published: (2024)

Treatment of inflammatory bowel disease with steroid‐sparing medications is age‐dependent – Results from a Danish nationwide cohort study, 2000–2018
by: Rie Louise Møller Nordestgaard, et al.
Published: (2024)

Editorial: Disordered eating and irritable bowel syndrome—Do maladaptive eating and weight control behaviours increase risk of a maladaptive gut?
by: Andrea Shin
Published: (2024)

Performance of bowel preparation quality scales in patients with Crohn's disease
by: Virginia Solitano, et al.
Published: (2024)

Maladaptive weight control and eating behaviours in female adolescents/young adults are associated with increased risk of irritable bowel syndrome in adulthood: Results from the Growing Up Today Study (GUTS)
by: Keming Yang, et al.
Published: (2024)

Impacts of glucagon‐like peptide‐1 receptor agonists on the risk of adverse liver outcomes in patients with metabolic dysfunction‐associated steatotic liver disease cirrhosis and type 2 diabetes
by: Mohamed I. Elsaid, et al.
Published: (2024)

Systematic review: Defining, diagnosing and monitoring small bowel strictures in Crohn's disease on intestinal ultrasound
by: Cathy Lu, et al.
Published: (2024)

Editorial: Mortality in immune‐mediated inflammatory diseases during early adulthood
by: Paul Henderson
Published: (2024)

Metabolic dysfunction‐associated steatotic liver disease and MetALD increases the risk of liver cancer and gastrointestinal cancer: A nationwide cohort study
by: Yewan Park, et al.
Published: (2024)

Letter: Irritable bowel syndrome and antibiotics
by: George F. Longstreth
Published: (2024)

Editorial: Mortality in immune‐mediated inflammatory diseases during early adulthood—Authors' reply
by: Mikkel Malham, et al.
Published: (2024)

Letter: Irritable bowel syndrome and antibiotics—Authors' reply
by: Kyle Staller, et al.
Published: (2024)

Terlipressin therapy is associated with increased risk of colonisation with multidrug‐resistant bacteria in patients with decompensated cirrhosis
by: Marcus M. Mücke, et al.
Published: (2024)

Long‐term clinical outcomes in steatotic liver disease and incidence of liver‐related events, cardiovascular events and all‐cause mortality
by: Nobuharu Tamaki, et al.
Published: (2024)